PHARMAC - Latest News [Page 1]
Pharmac Proposing To Fund Two Brands Of Oestradiol Patches
Thursday, 27 March 2025, 1:54 pm | PHARMAC
If approved, Pharmac would fund both brands of oestradiol patches from 1 December 2025 and people could use either brand of patch, subject to availability. The public consultation opens on 27 March and closes on 22 April. More >>
Pharmac Proposes To Fund More Medicines For Melanoma
Thursday, 20 March 2025, 1:53 pm | PHARMAC
Pharmac’s Director Pharmaceuticals, Geraldine MacGibbon, says funding these medicines would provide more treatment options to use around the time of surgery, or if people’s cancer is at a later stage and they can’t have surgery. More >>
Search For Pharmac's New CE Underway
Friday, 14 March 2025, 10:47 am | PHARMAC
Board Chair Paula Bennett says the Board is looking for a mix of strategic and operational leadership to help Pharmac become a more outward-focused, empathetic organisation. More >>
New Insulin Medicine Proposed For People With Diabetes
Monday, 10 March 2025, 1:06 pm | PHARMAC
The new medicine (branded as Ryzodeg) is a combination of two other medicines: insulin degludec (an ultra-long-acting insulin) and insulin aspart (a rapid-acting insulin). More >>
Pharmac Committed To Stronger, More Inclusive Consumer Relationships
Monday, 10 March 2025, 10:34 am | PHARMAC
The report was prepared for the Board following two workshops with advocacy groups representing people with lived experience of health conditions. The Board commissioned the workshops, which were independently chaired by Dame Kerry Prendergast in Wellington ... More >>
Pharmac CE Resigns
Friday, 28 February 2025, 2:51 pm | PHARMAC
The Board and Pharmac are appreciative of all of Sarah's work over her times as Chief Executive and her previous 5 years in Senior Executive roles in the organisation. More >>
Pharmac Close To Finalising Proposal For More Than One Brand Of Oestradiol Patch
Wednesday, 26 February 2025, 2:34 pm | PHARMAC
Pharmac is in discussions with the suppliers of Estradot and Estradiol TDP Mylan patches and Dr Ngawati says these talks have been progressing well. The oestradiol patches currently in use will continue to be available as Pharmac works through this ... More >>
Proposal To Fund A New Oral Contraceptive Pill
Monday, 3 February 2025, 1:41 pm | PHARMAC
Pharmac’s Clinical Lead–Medicines Management, Melissa Copland, says about 43,000 people are expected to benefit from desogestrel in the first full year of funding. Public consultation on the funding proposal is now open and will close on 18 February. More >>
Pharmac Reconsiders Oestradiol Patch Options Following Community Feedback
Wednesday, 29 January 2025, 5:53 pm | PHARMAC
“While the global shortage has not been solved by any stretch, we are looking at what we can do to ensure that people can get the best patches for their personal situations,” says Pharmac’s Senior Therapeutic Group Manager/Team Leader, Alexandra ... More >>
Consultations For Cancer And ADHD Medicines Close Soon
Wednesday, 22 January 2025, 9:21 am | PHARMAC
Geraldine MacGibbon, Pharmac’s Director Pharmaceuticals, says there’s just under one week left to give feedback on the proposals to fund six medicines for cancer, one for antibiotic resistant infections, and a brand change of a breast cancer medicine. More >>
Pharmac Consulting On Widening Access To Venetoclax, Azacitidine And Upadacitinib
Thursday, 16 January 2025, 1:21 pm | PHARMAC
Pharmac currently funds venetoclax for a different type of blood cancer called chronic lymphocytic leukaemia, and funds upadacitinib for some people with rheumatoid arthritis. Azacitidine is currently funded for other types of blood cancer. More >>
2,000 People To Benefit From Medicine For Osteoporosis And People With High Blood Calcium And Cancer
Friday, 10 January 2025, 2:18 pm | PHARMAC
In their consultation feedback, Osteoporosis NZ applauded Pharmac on the proposal. They believe this will be a game changer and will greatly improve and enhance the current deficiencies associated with fragility fracture prevention in New Zealand. More >>
Pharmac Consulting On Six Medicines For New Zealanders
Thursday, 19 December 2024, 1:14 pm | PHARMAC
The new medicines are part of multiproduct agreements with two suppliers which is why the consultations include multiple medicines. Consultation is now open, and people can submit feedback through the Pharmac website before 24 January 2025. More >>
Pharmac Is Exploring Options For Alternative Brands Of Oestradiol Patches
Wednesday, 18 December 2024, 9:27 am | PHARMAC
“We’ll be seeking feedback about access to alternative brands through a public consultation before making any decisions. The consultation will be provided to key stakeholders & interested groups, including the organisers of a recent petition, ... More >>
Consultation To Increase ADHD Medicine Access Begins
Tuesday, 17 December 2024, 2:31 pm | PHARMAC
The proposal suggests broadening the range of people who can initiate treatment of stimulant medicines which, over time, would lead to more doctors and nurse practitioners being able to diagnose and treat ADHD. More >>
Skin Cream To Treat Infections Becomes Fully Funded
Friday, 13 December 2024, 11:15 am | PHARMAC
“We expect about 780 people to benefit from it being fully funded in the first year. This is a small step to help people treat and heal from their skin infections so they can continue with their daily lives.” More >>
Pharmac Seeks Feedback To Fund Medicines For Liver And Ovarian Cancer
Monday, 9 December 2024, 2:05 pm | PHARMAC
The proposal also includes widening access to another medicine, atezolizumab (branded as Tecentriq), which is used with bevacizumab for liver cancer that cannot be removed by surgery. More >>
Update On Oestradiol Patches Supply Issues
Thursday, 28 November 2024, 5:00 pm | PHARMAC
“It’s been very challenging to get an ongoing supply of oestradiol in the midst of a global shortage and we’re hoping that the combination of the oestradiol gel and the new patches will solve the shortages here in New Zealand.” More >>
Pharmac Changes Brand Of Funded Oestradiol Patches
Monday, 25 November 2024, 11:03 am | PHARMAC
The company, Viatris, has been contracted to supply Estradiol TDP Mylan from 1 July 2025, conditional on Viatris gaining full regulatory approval for use in New Zealand. More >>
New Heart Medicine For 18,000 New Zealanders
Tuesday, 12 November 2024, 8:15 pm | PHARMAC
Pharmac funded empagliflozin for the first time in 2020 for some people with type 2 diabetes as it also helps to keep the levels of sugar in the blood in the healthy range. More >>